Syndicate content

Archive - Jun 11, 2017

New Trends and Emerging Technologies Are Focus of Morning Session on Day 2 of Personalized Medicine World Conference (PMWC) 2017 at Duke

After the morning’s opening panel discussion on “The Value of Data Sharing,” Day 2 of the Personalized Medicine World Conference (PMWC) 2017 at Duke continued with a high-energy, high-impact presentation by Mark Levin (photo), Co-Founder of Third Rock Ventures in the session on “New Trends and Emerging Technologies.” Other speakers in this session included John Mikszta PhD, Director of the Genomic Sciences Focus Area at BD Technologies; Lawrence David, PhD, Assistant Professor, Department of Molecular Genetics and Microbiology and Center for Genomics & Computational Biology at Duke University; and Panna Sharma, President and CEO, Cancer Genetics, Inc. Dr. Mikszta spoke on ”Single-Cell Genomics: Emerging Applications,” Dr. David spoke on “The Role of the Human Microbiome,”and Dr. Sharma spoke on “How AI Is Accelerating and Enabling Precision Oncology.” Mark Levin has been a life science leader for 40 years, most of them spent conceiving and launching biotechnology companies. Early on, Levin recognized that personalized medicine had the potential to benefit the patient and revolutionize both pharma and biotech. He strongly espoused that the only way the field would reach this potential was if all stakeholders banded together to overcome the many challenges it faced. To enable this, he helped conceive the Personalized Medicine Coalition. In 2007, Levin co-founded Third Rock Ventures, a different kind of venture capital firm that actively searched for disruptive medical technology and innovative science, to build into companies from the ground up. Many of these were based on personalized medicine, such as cancer epigenetics, gene therapy and molecular diagnostics. Then, he and his partners carefully selected the founding teams and instilled them with a sustainable culture.